ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START San Antonio

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Budigalimab
Nivolumab
PF-07220060
pembrolizumab
Docetaxel
SRF388
Methylthioadenosine
PF-07265028
FMC-376

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

52 of 65 total trials

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Active, not recruiting
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

The purpose of this study is to evaluate the safety and tolerability of:* AB521 when taken alone in participants with advanced solid tumor malignanci...

Enrolling
Solid Tumors
Clear Cell Renal Cell Carcinoma
Drug: AB521
Drug: Cabozantinib

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling
Advanced Solid Tumors
Drug: RO7623066
Drug: Olaparib

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Solid Tumor, Adult
Unresectable Solid Tumor
Drug: FMC-376

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0706

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or re...

Enrolling
Advanced MTAP-null Solid Tumors
Drug: Comparator AMG 193 Test Tablet
Drug: Docetaxel

The primary objectives of this study are to:* Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in...

Enrolling
Advanced Solid Tumors
Drug: AMG 355
Drug: Pembrolizumab

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209...

Enrolling
Endometrial Cancer
Lymphoma, T-Cell
Drug: CPI-0209

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.The mai...

Enrolling
Open Label
Oral Drug Administration
Drug: FX-909

The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose e...

Enrolling
Advanced Prostate Cancer
Drug: JNJ-78278343
Drug: JNJ-87189401

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast c...

Enrolling
Breast Cancer
Drug: LOXO-783
Drug: Abemaciclib

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in part...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metast...

Not yet enrolling
Esophageal Cancer
Advanced Solid Tumor
Drug: LY4052031

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metast...

Enrolling
Esophageal Cancer
Advanced Solid Tumor
Drug: LY4101174
Recently updated

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it...

Enrolling
Uterine Cervical Neoplasms
Ovarian Neoplasms
Drug: carboplatin
Drug: pembrolizumab

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A sid...

Enrolling
Ovarian Neoplasms
Adenoid Cystic Carcinoma
Drug: SGN-B7H4V

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Drug: SGN-CEACAM5C

This study will test the safety of a drug called SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the sid...

Enrolling
Ovarian Neoplasms
Melanoma
Drug: SGN-PDL1V
Drug: pembrolizumab

Trial sponsors

Lilly logo
Incyte logo
AbbVie logo
Pfizer logo
Seagen logo
Merck Sharp & Dohme (MSD) logo
Mirati Therapeutics logo
Amgen logo
C
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems